QIAGEN joins CANCER-ID consortium for liquid biopsy workflows
Public-private partnership aims to standardize and clinically validate blood-based biomarkers
31-Mar-2017 -
QIAGEN N.V. announced it has joined CANCER-ID, a public-private consortium aiming to establish standard protocols and clinical validation for blood-based biomarkers in lung and breast cancer.
Rapid advances in the use of liquid biopsies, which enable cancer treatment and monitoring through the ...
biopsies
cancer
cancer biomarkers
+9